Pharma News

Revenue for Nusinersen is expected to have a CAGR of -16.2% through 2038

Nusinersen is a Antisense Oligonucleotide owned by Biogen, and is involved in 18 clinical trials, of which 8 were completed, 9 are ongoing, and 1 is planned.

Nusinersen is SMN2 gene activator. ISIS-SMNRx compensates for the defect by promoting the production of functional SMN protein. Spinal muscular atrophy is caused by a loss or defect in the survival motor SMN1 gene leading to a decrease in the protein SMN. SMN1 gene produces functional SMN protein in healthy humans. SMN2 gene produces a small amount of SMN protein. ISIS-SMNRx enables the SMN2 gene to produce more functional SMN protein by modulating a cellular process, splicing. The drug candidate keeps exon 7 in the RNA which leads to the production of functional SMN protein.

The revenue for Nusinersen is expected to reach a total of $14.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nusinersen NPV Report.

Nusinersen is currently owned by Biogen.

Nusinersen Overview

Nusinersen (Spinraza) is an antisense oligonucleotide. It is formulated as a powder for solution and solution for the intrathecal route of administration. Spinraza is indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. ISIS-SMNRx is based on antisense technology platform.

Biogen Overview

Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$10,981.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.3% over FY2020. In FY2021, the company’s operating margin was 25.9%, compared to an operating margin of 33.8% in FY2020. In FY2021, the company recorded a net margin of 14.2%, compared to a net margin of 29.8% in FY2020.
The company reported revenues of US$2,508.5 million for the third quarter ended September 2022, a decrease of 3.1% over the previous quarter.

Quick View – Nusinersen

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
Key Companies
Highest Development Stage

Source link
#Revenue #Nusinersen #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *